Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| MEDP | Medpace Holdings, Inc. | 2026-02-17 17:58:38 | 423.48 | -4.7 | -1.1 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MEDP | 0001668397 | Medpace Holdings, Inc. | US58506Q1094 | 549300H8TYEUVTW14A54 | 320434904 | Nasdaq | 8731 | Services-Commercial Physical & Biological Research | 1231 | DE | 5375 MEDPACE WAY | CINCINNATI | OH | 45227 | UNITED STATES | US | (513) 579-9911 | 5375 MEDPACE WAY, CINCINNATI, OH, 45227 | 5375 MEDPACE WAY, CINCINNATI, OH, 45227 | — | Contract Research Organization | 1992 | August J. Troendle | 6,041 | http://medpace.com | 7,000,000,000 | 28,370,780 | 28,381,283 | Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio. | 2026-02-12 15:54:57 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 7,000,000,000 | -3,500,000,000 | -33.3333 | 28,381,283 | -2,085,523 | -6.8452 |
| 2024 | 10,500,000,000 | 4,900,000,000 | 87.5 | 30,466,806 | -292,475 | -0.9509 |
| 2023 | 5,600,000,000 | 1,900,000,000 | 51.3514 | 30,759,281 | -290,879 | -0.9368 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Susan E. Burwig | Executive Vice President | 2019 | 419,099 | 150,000 | 700,003 | 0 | 64,120 | 2,429,461 |
| Stephen P. Ewald | Corporate Secretary, General Counsel | 2019 | 299,791 | 110,000 | 300,040 | 0 | 5,998 | 1,253,572 |
| August J. Troendle | Chief Executive Officer, President | 2019 | 503,583 | 0 | 1,163,914 | 0 | 88,978 | 7,712,835 |
| Jesse J. Geiger | Chief Financial Officer, Chief Operating Officer | 2019 | 409,475 | 0 | 573,997 | 0 | 9,500 | 1,883,882 |
| August J. Troendle | Chief Executive Officer, President | 2018 | 420,250 | 0 | 0 | 0 | 108,040 | 528,290 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 6,200 |
| 2024 | 5,900 |
| 2023 | 5,900 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 2,530,234,000 | 2,109,054,000 | 1,885,842,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | — | — | — |
| General And Administrative Expenses | 197,559,000 | 180,184,000 | 161,352,000 |
| Operating Expenses | 1,769,616,000 | 1,452,749,000 | 1,361,337,000 |
| Operating Income | 534,935,000 | 446,870,000 | 336,825,000 |
| Net Income | 451,123,000 | 404,386,000 | 282,810,000 |
| Earnings Per Share Basic | 15.64 | 13.06 | 9.2 |
| Earnings Per Share Diluted | 15.28 | 12.63 | 8.88 |
| Weighted Average Shares Outstanding Basic | 28,846,000 | 30,957,000 | 30,722,000 |
| Weighted Average Shares Outstanding Diluted | 29,527,000 | 32,014,000 | 31,841,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 497,049,000 | 669,436,000 | 245,449,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 402,078,000 | 296,443,000 | 298,400,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 989,624,000 | 1,029,229,000 | 593,828,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 131,055,000 | 123,615,000 | 120,589,000 |
| Other Assets Non Current | 21,939,000 | 22,254,000 | 24,970,000 |
| Total Assets Non Current | 985,848,000 | 1,071,637,000 | 1,063,000,000 |
| Total Assets | 1,975,472,000 | 2,100,866,000 | 1,656,828,000 |
| Accounts Payable | 28,142,000 | 32,528,000 | 31,869,000 |
| Deferred Revenue | 854,390,000 | 710,585,000 | 559,860,000 |
| Short Term Debt | — | — | 0 |
| Other Liabilities Current | 52,834,000 | 53,633,000 | 40,441,000 |
| Total Liabilities Current | 1,343,748,000 | 1,104,553,000 | 925,131,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 57,655,000 | 42,734,000 | 28,221,000 |
| Total Liabilities Non Current | 172,653,000 | 170,768,000 | 172,747,000 |
| Total Liabilities | 1,516,401,000 | 1,275,321,000 | 1,097,878,000 |
| Common Stock | 284,000 | 306,000 | 308,000 |
| Retained Earnings | -459,981,000 | 8,167,000 | -221,645,000 |
| Accumulated Other Comprehensive Income | -4,906,000 | -14,743,000 | -10,072,000 |
| Total Shareholders Equity | 459,071,000 | 825,545,000 | 558,950,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 27,178,000 | 27,808,000 | 24,129,000 |
| Share Based Compensation Expense | 34,786,000 | 25,514,000 | 20,516,000 |
| Other Non Cash Income Expense | 875,000 | 4,009,000 | -2,705,000 |
| Change In Accounts Receivable | 106,215,000 | -2,242,000 | 48,282,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 2,629,000 | -2,965,000 | 1,051,000 |
| Change In Other Liabilities | -11,237,000 | -23,794,000 | 9,607,000 |
| Cash From Operating Activities | 713,223,000 | 608,815,000 | 433,374,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 31,356,000 | 36,548,000 | 36,648,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | -216,000 | -8,240,000 | -2,019,000 |
| Cash From Investing Activities | -31,140,000 | -28,308,000 | -34,629,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 917,389,000 | 169,867,000 | 144,020,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 0 | 0 | 155,000,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -860,388,000 | -154,009,000 | -182,642,000 |
| Change In Cash | -172,387,000 | 423,987,000 | 217,184,000 |
| Cash At End Of Period | 497,049,000 | 669,436,000 | 245,449,000 |
| Income Taxes Paid | 39,719,000 | 83,567,000 | 76,353,000 |
| Interest Paid | 0 | 171,000 | 3,056,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 15.64 | 13.06 | 9.2 |
| Price To Earnings Ratio | 35.9111 | 25.4387 | 33.3185 |
| Earnings Growth Rate | 19.755 | 41.9565 | 21.5324 |
| Price Earnings To Growth Ratio | 1.8178 | 0.6063 | 1.5474 |
| Book Value Per Share | 15.9145 | 26.6675 | 18.1938 |
| Price To Book Ratio | 35.2916 | 12.4582 | 16.848 |
| Ebitda | 518,020,000 | 515,761,000 | 383,292,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 34,618,000 | 30,834,000 | 34,869,000 |
| Free Cash Flow | 678,605,000 | 577,981,000 | 398,505,000 |
| Return On Equity | 0.9827 | 0.4898 | 0.506 |
| One Year Beta | 0.9677 | 1.263 | 1.2282 |
| Three Year Beta | 1.0929 | 1.2921 | 1.2818 |
| Five Year Beta | 1.1967 | 1.2452 | 1.2531 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| BURWIG SUSAN E | Exec. VP, Operations | 2026-02-13 | 10,984 | A | 58,484 |
| BURWIG SUSAN E | Exec. VP, Operations | 2026-02-13 | 10,984 | D | 0 |
| Carley Brian T | Director | 2026-02-13 | 6,472 | A | 32,753 |
| Carley Brian T | Director | 2026-02-13 | 6,472 | D | 0 |
| Kraft Robert O. | Director | 2025-12-31 | 56 | A | 889 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | 2026-02-13 | CA31 | Sale | 2026-01-15 | — | $15,001 - $50,000 |
| David J. Taylor | 2026-02-02 | OH02 | Sale | 2026-01-16 | — | $1,001 - $15,000 |
| David J. Taylor | 2026-02-02 | OH02 | Purchase | 2026-01-29 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2025-11-18 | CA31 | Sale (Partial) | 2025-10-09 | — | $1,001 - $15,000 |
| Lisa McClain | 2025-09-12 | MI09 | Sale | 2025-08-04 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| EP Wealth Advisors, LLC | 2025-12-31 | 280,825 | 500 | 561.65 |
| AMERIFLEX GROUP, INC. | 2025-12-31 | 28,083 | 50 | 561.66 |
| MERCER GLOBAL ADVISORS INC /ADV | 2025-12-31 | 15,762,138 | 28,064 | 561.6497 |
| RAYMOND JAMES FINANCIAL INC | 2025-12-31 | 50,227,323 | 89,294 | 562.4938 |
| Abel Hall, LLC | 2025-12-31 | 202,194 | 360 | 561.65 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Value Line Small Cap Opportunities Fund, Inc. | 2025-12-31 | Institutional | VLEIX | 32,500 | 18,253,625 | 2.2266 |
| Value Line Small Cap Opportunities Fund, Inc. | 2025-12-31 | Value Line Small Cap Opportunities Fund, Inc. | VLEOX | 32,500 | 18,253,625 | 2.2266 |
| WASATCH FUNDS TRUST | 2025-12-31 | Institutional Class Shares | WGLSX | 3,031 | 1,702,361.15 | 4.4793 |
| WASATCH FUNDS TRUST | 2025-12-31 | Investor Class Shares | WALSX | 3,031 | 1,702,361.15 | 4.4793 |
| WASATCH FUNDS TRUST | 2025-12-31 | Institutional Class Shares | WIGOX | 3,797 | 2,132,585.05 | 1.3422 |